• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于测定新型布鲁顿酪氨酸激酶抑制剂司布替尼的高灵敏度液相色谱-串联质谱法:在代谢稳定性评估中的应用

A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation.

作者信息

Abdelhameed Ali S, Attwa Mohamed W, Al-Shaklia Nasser S, Kadi Adnan A

机构信息

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia.

Students' University Hospital, Mansoura University, Mansoura 35516, Egypt.

出版信息

R Soc Open Sci. 2019 Jun 5;6(6):190434. doi: 10.1098/rsos.190434. eCollection 2019 Jun.

DOI:10.1098/rsos.190434
PMID:31312501
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6599791/
Abstract

Spebrutinib (SBT) is a Bruton's tyrosine kinase inhibitor. SBT is currently in phase II and phase I clinical trials for the management of rheumatoid arthritis and chronic lymphocytic leukaemia, respectively. We developed and validated a liquid chromatography tandem mass spectrometry analytical method to quantify SBT and investigate its metabolic stability. SBT and the naquotinib as internal standard were isocratically eluted on a C18 column. The linearity of the developed method is 5-500 ng ml ( ≥ 0.9999) in the human liver microsomes (HLMs) matrix. Good sensitivity was approved by the very low limit of detection (0.39 ng ml). Inter- and intra-assay accuracy values of -1.41 to 12.44 and precision values of 0.71% to 4.78%, were obtained. SBT was found to have an half-life (82.52 min) and intrinsic clearance (8.4 µl min mg) as computed following its incubation with HLMs. The latter finding, hypothesize that SBT could be slowly excreted from the body unlike other related tyrosine kinase inhibitors. So, drug plasma level and kidney function should be monitored because of potential bioaccumulation. To the best of our knowledge, this is considered the first analytical method for SBT quantification using LC-MS/MS with application to metabolic stability evaluation.

摘要

司布替尼(SBT)是一种布鲁顿酪氨酸激酶抑制剂。目前,SBT分别处于类风湿性关节炎和慢性淋巴细胞白血病治疗的II期和I期临床试验阶段。我们开发并验证了一种液相色谱串联质谱分析方法,用于定量SBT并研究其代谢稳定性。SBT和作为内标的那喹替尼在C18柱上进行等度洗脱。所开发方法在人肝微粒体(HLM)基质中的线性范围为5 - 500 ng/ml(≥0.9999)。极低的检测限(0.39 ng/ml)证明了该方法具有良好的灵敏度。批间和批内准确度值在-1.41至12.44之间,精密度值在0.71%至-4.78%之间。SBT与HLM孵育后计算得出的半衰期为82.52分钟,内在清除率为8.4 μl·min/mg。后一项发现表明,与其他相关酪氨酸激酶抑制剂不同,SBT可能从体内缓慢排泄。因此,由于存在潜在的生物蓄积,应监测药物血浆水平和肾功能。据我们所知,这被认为是第一种使用LC-MS/MS定量SBT并应用于代谢稳定性评估的分析方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/a59a465582f0/rsos190434-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/c496f66d88e0/rsos190434-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/3694fbad085d/rsos190434-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/4214ab1e3ca0/rsos190434-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/c1701a3ff5fe/rsos190434-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/70067f6c9b2b/rsos190434-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/a59a465582f0/rsos190434-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/c496f66d88e0/rsos190434-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/3694fbad085d/rsos190434-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/4214ab1e3ca0/rsos190434-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/c1701a3ff5fe/rsos190434-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/70067f6c9b2b/rsos190434-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4711/6599791/a59a465582f0/rsos190434-g6.jpg

相似文献

1
A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation.一种用于测定新型布鲁顿酪氨酸激酶抑制剂司布替尼的高灵敏度液相色谱-串联质谱法:在代谢稳定性评估中的应用
R Soc Open Sci. 2019 Jun 5;6(6):190434. doi: 10.1098/rsos.190434. eCollection 2019 Jun.
2
LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes.LC-MS/MS 法测定抗癌药物英菲格拉替尼的含量:在人肝微粒体中评价代谢稳定性的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Aug 1;1179:122806. doi: 10.1016/j.jchromb.2021.122806. Epub 2021 Jul 2.
3
LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation.LC-MS/MS 法测定人肝微粒体中的罗西替尼浓度:用于代谢稳定性评估。
Drug Des Devel Ther. 2021 Sep 15;15:3915-3925. doi: 10.2147/DDDT.S321330. eCollection 2021.
4
Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation.建立一种 LC-MS/MS 法用于人肝微粒体中萨匹替尼的定量分析:体外和体内代谢稳定性评价。
Molecules. 2023 Mar 2;28(5):2322. doi: 10.3390/molecules28052322.
5
Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies.采用经验证的 LC-MS/MS 方法评估新型 PARP 抑制剂他拉唑帕尼的代谢稳定性:基于计算的代谢脆弱性和毒理学研究。
Drug Des Devel Ther. 2020 Feb 25;14:783-793. doi: 10.2147/DDDT.S239458. eCollection 2020.
6
Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study.建立并验证 HPLC-MS/MS 法测定选择性 Janus 激酶 1 抑制剂 filgotinib:应用于代谢稳定性研究。
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122195. doi: 10.1016/j.jchromb.2020.122195. Epub 2020 May 30.
7
Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability.经验证的 LC-MS/MS 分析测定法,用于定量新型批准的酪氨酸激酶抑制剂达可替尼,并应用于研究其代谢稳定性。
PLoS One. 2019 Apr 4;14(4):e0214598. doi: 10.1371/journal.pone.0214598. eCollection 2019.
8
Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method.采用经验证的 LC-MS/MS 方法评估人肝微粒体中塞普替尼的体内和体外代谢稳定性。
Molecules. 2023 Mar 14;28(6):2618. doi: 10.3390/molecules28062618.
9
Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry.使用液相色谱串联质谱法对拉罗替尼进行代谢稳定性评估。
Drug Des Devel Ther. 2020 Jan 10;14:111-119. doi: 10.2147/DDDT.S235934. eCollection 2020.
10
Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes.开发并验证一种快速 LC-MS/MS 法用于定量测定阿伐卡必:人肝微粒体中的体外和体内代谢稳定性预测。
Molecules. 2023 Mar 4;28(5):2368. doi: 10.3390/molecules28052368.

引用本文的文献

1
Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring.用于药代动力学研究和治疗药物监测的生物样品中酪氨酸激酶抑制剂的预处理及分析技术开发
J Pharm Anal. 2024 Apr;14(4):100899. doi: 10.1016/j.jpha.2023.11.006. Epub 2023 Nov 28.
2
Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes.开发并验证一种快速 LC-MS/MS 法用于定量测定阿伐卡必:人肝微粒体中的体外和体内代谢稳定性预测。
Molecules. 2023 Mar 4;28(5):2368. doi: 10.3390/molecules28052368.
3

本文引用的文献

1
Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: phase I metabolic investigation.通过液相色谱-串联质谱法表征达可替尼代谢过程中反应中间体的形成并阐明生物活化途径:I期代谢研究
RSC Adv. 2018 Nov 19;8(68):38733-38744. doi: 10.1039/c8ra06709k. eCollection 2018 Nov 16.
2
Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma.采用经验证的液相色谱-串联质谱法(LC-MS/MS)研究奥美替尼的代谢稳定性:人血浆中的定量分析。
RSC Adv. 2018 Dec 4;8(70):40387-40394. doi: 10.1039/c8ra08161a. eCollection 2018 Nov 28.
3
A Novel Green Micellar HPLC-UV Method for the Estimation of Vandetanib in Pure Form, Human Urine, Human Plasma and Human Liver Microsomes Matrices with Application to Metabolic Stability Evaluation.
一种新型绿色胶束 HPLC-UV 法用于纯品、人尿、人血浆和人肝微粒体基质中凡德他尼的测定及其在代谢稳定性评价中的应用。
Molecules. 2022 Dec 18;27(24):9038. doi: 10.3390/molecules27249038.
4
A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes.一种经验证的用于定量培米替尼的液相色谱-串联质谱分析方法:在人肝微粒体中的代谢稳定性评估。
RSC Adv. 2022 Jul 13;12(31):20387-20394. doi: 10.1039/d2ra02885a. eCollection 2022 Jul 6.
5
Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.用于治疗免疫性疾病的布鲁顿激酶抑制剂:现状与展望
J Clin Med. 2022 May 16;11(10):2807. doi: 10.3390/jcm11102807.
6
Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.布鲁顿酪氨酸激酶抑制用于类风湿关节炎的治疗
Immunotargets Ther. 2021 Aug 28;10:333-342. doi: 10.2147/ITT.S288550. eCollection 2021.
7
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.靶向癌症治疗中的小分子:进展、挑战和未来展望。
Signal Transduct Target Ther. 2021 May 31;6(1):201. doi: 10.1038/s41392-021-00572-w.
8
Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach.应用 LC-MS/MS 技术在人肝微粒体中对抗癌药物恩沙替尼的稳定和反应性代谢物进行特征分析:一种基于计算和实际生物转化的方法。
Drug Des Devel Ther. 2020 Nov 30;14:5259-5273. doi: 10.2147/DDDT.S274018. eCollection 2020.
9
Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation.使用 LC-MS/MS 鉴定替泊替尼代谢中的亚胺中间体生成:生物活化途径阐明的计算和实际方法。
Molecules. 2020 Oct 28;25(21):5004. doi: 10.3390/molecules25215004.
A simple liquid chromatography-tandem mass spectrometry method to accurately determine the novel third-generation EGFR-TKI naquotinib with its applicability to metabolic stability assessment.
一种简单的液相色谱-串联质谱法,用于准确测定新型第三代表皮生长因子受体酪氨酸激酶抑制剂那喹替尼及其在代谢稳定性评估中的适用性。
RSC Adv. 2019 Feb 7;9(9):4862-4869. doi: 10.1039/c8ra09812c. eCollection 2019 Feb 5.
4
Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability.经验证的 LC-MS/MS 分析测定法,用于定量新型批准的酪氨酸激酶抑制剂达可替尼,并应用于研究其代谢稳定性。
PLoS One. 2019 Apr 4;14(4):e0214598. doi: 10.1371/journal.pone.0214598. eCollection 2019.
5
Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.阿卡拉布替尼,第二代布鲁顿酪氨酸激酶抑制剂。
Recent Results Cancer Res. 2018;212:285-294. doi: 10.1007/978-3-319-91439-8_14.
6
Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS.运用 LC-MS/MS 技术对新型 ALK 抑制剂(Entrectinib)的代谢降解进行研究。
Clin Chim Acta. 2018 Oct;485:298-304. doi: 10.1016/j.cca.2018.07.009. Epub 2018 Jul 10.
7
A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate.一种通过液相色谱-串联质谱法测定人血浆中福瑞替尼的可靠且稳定的方法:在代谢稳定性研究和排泄率中的应用。
Eur J Mass Spectrom (Chichester). 2018 Aug;24(4):344-351. doi: 10.1177/1469066718768327. Epub 2018 Apr 8.
8
Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry.采用液相色谱-串联质谱法研究新型 ALK 抑制剂布加替尼的代谢稳定性。
Clin Chim Acta. 2018 May;480:180-185. doi: 10.1016/j.cca.2018.02.016. Epub 2018 Feb 16.
9
LC-MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate.用于定量测定微粒体(RLMs)基质和大鼠尿液中马西替尼的液相色谱-串联质谱(LC-MS/MS)方法:在代谢稳定性和排泄率方面的应用
Chem Cent J. 2017 Dec 22;11(1):136. doi: 10.1186/s13065-017-0365-2.
10
Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation.液相色谱串联质谱法测定人血浆和大鼠肝微粒体基质中凡德他尼的含量:代谢稳定性研究
Chem Cent J. 2017 May 30;11(1):45. doi: 10.1186/s13065-017-0274-4.